ATANIS Biotech, a Swiss biotechnology company specializing in advanced allergy diagnostics, has successfully completed an oversubscribed financing round led by Spectrum Moonshot Fund and supported by experienced investors in the allergy field. The funds will be used to ramp up marketing efforts for ATANIS’s cutting-edge FAST-PASE® allergy test in the U.S. and Europe. This innovative diagnostic tool is designed to address the growing need for safer and more accurate functional allergy testing solutions.

VISCHER advised ATANIS Biotech AG in this transaction. The team consisted of Gian-Andrea Caprez and Sandro Bernet (both Corporate/M&A).

Author: Gian-Andrea Caprez